

Challenge of Antimicrobial Drug Resistance

Subjects: **Microbiology**

Contributor: Tariq Khan

Antimicrobial resistance is mushrooming as a silent pandemic. It is considered among the most common priority areas identified by both national and international agencies. The global development of multidrug-resistant strains now threatens public health care improvement by introducing antibiotics against infectious agents.

antimicrobial resistance

ESKAPE

bacteria

antibiotics

1. Introduction

In the mid-20th century, when the clinical practice of antimicrobial drugs was introduced, it revolutionized the public health sector ^[1]. The infectious microorganisms that had threatened human survival are now at the mercy of different chemical compounds. The introduction of antibiotics significantly reduced the risks linked with childbirth, injuries, and intrusive medical procedures ^[2]. On the other side, what has been observed in the last 70 years is ongoing microbial experimentation on a large scale and the haphazard use of antimicrobials in large amounts. This poses a genuine threat to human beings by pathogenic bacteria that acquire antimicrobial resistance. This alarms a coming time where common infections are as untreatable as in the pre-antimicrobial era ^[3]. It is assessed that by 2050, 10 million lives may be lost per year due to antimicrobial resistance. This exceeds the number currently lost due to cancer, 8.2 million lives ^[4]. To put this figure in perspective, every year, 700,000 people die globally due to acquired resistance against different antimicrobials, more than the total number of deaths caused by measles, cholera, and tetanus. The drivers of antimicrobial resistance are lesser knowledge about the best-applied practice of antibiotic stewardship and its education ^[5]; overuse of inappropriate antibiotics; unfair practices such as under or overdosing to treat minor bacterial, fungal, or viral infections; and most importantly the uncontrolled use of antibiotics in animal's food to increase their meat production ^[6]. It is feared that if the current rise in antimicrobial resistance continues, the world economies will be hit by a loss of \$100 trillion by the year 2050 ^[7]. As efforts are being made in research and development to find better antibacterial drugs, more research is performed in areas like CRISPER/Cas9, vaccines, and nanotechnology. The world health organization recognized these alternatives as essential and highly effective tools to mitigate antimicrobial resistance.

2. Drivers of Antimicrobial Resistance

During the 1960s, the first bacteria showing resistance to multiple drugs were *Shigella*, *Salmonella*, and *Escherichia coli* ^{[8][9][10]}. The increase in antimicrobial-resistant bacteria/pathogens poses a serious threat to the health sector and leads to extra-economic burdens. One of the significant contributors to this increasing antimicrobial use are the health care systems fighting against it, which allow inappropriate prescriptions and

availability of antimicrobials without prescription to the patients, especially in developing countries. All this is then backed by the poor sanitation services, which aid the transmission, and low healthcare budgets have to rely on cheap antibiotics instead of the safer but more expensive ones [\[11\]](#).

We are not creating antimicrobial resistance; we are simply endorsing it by putting on selective evolutionary pressure, which will result in the evolution of numerous genetic mechanisms [\[12\]](#). Mechanisms by which antibiotics imply selective pressure are poorly understood. We have represented the genetic mechanism of antimicrobial resistance in the ESKAPE pathogen in [Figure 1](#). Routes associated with antimicrobial resistance are dynamic and less predictable. Problems related to antimicrobial resistance can be assessed by simply recognizing two components: the antimicrobials that inhibit an organism's susceptibility and the resistant genetic determinants in the microorganism selected by antimicrobials [\[13\]\[14\]](#). Subsequently, the resistance emerges when these two components interact in an environment or hosts, leading to several clinical problems. Over the years, constant evolution has led to the emergence of that *Enterobacteriaceae* strains, which have both MDR (multidrug-resistant) and XDR (extensively drug-resistant) strains [\[15\]](#), to nearly all antibiotics available, without any promising treatment alternatives [\[16\]](#).




Figure 1. Genetic mechanism of Antimicrobial resistance in ESKAPE pathogen.

Bacterial strains are tremendously effective vehicles to spread the antibiotic resistance traits, transferring them horizontally through mobile genetic elements (transposons and plasmids) or vertically to its daughter cells and other species [\[17\]](#). These genes usually confer resistance against a single group or a family of antibiotics. A high level of resistance arises through sequential mutation in chromosomes, in the absence of plasmids and transposons, which typically mediate high-level resistance [\[18\]\[19\]\[20\]](#). This scenario was the foremost reason for the

initial emergence of penicillin and tetracycline resistance in *Neisseria gonorrhoeae*. Likewise, a group of *Enterobacteriaceae* acquired resistance to fluoroquinolones due to mutations in topoisomerase enzymes that alter gene expression and accelerate the membrane proteins that pump the drug out of the cell [18][20][21]. Resistant *Staphylococcus aureus* strains first appeared in response to vancomycin [22], followed by high-level resistant transposon from *Enterococci* [23][24]. An effective administration of contemporary antimicrobials, and the sustained development of the novel candidate, is crucial to protect human and animal health against bacterial pathogens [25].

3. Global Dissemination of Antibiotic Resistance

Several studies have been conducted on different samples of resistome from various environments, including studies of human and animal gut microflora, soil, and wastewater microbial communities [26][27]. Meanwhile, it has become clearly understood that ARGs (antimicrobial-resistant genes) related to clinical sides are prevalent in the environment [28]. Studies utilize metagenomics approaches to directly recover DNA from all microorganisms in a biological sample to investigate the resistome properly. Massive data has been generated from the sequencing of metagenomes and placed in databases. Such data will help in resolving different public health concerns. However, these studies' data is only limited to identifying genes or predicting novel sequence-based on the same homology to the known reported sequence. Annotation by using sequence-based studies and functional genomics revealed the already known ARGs, which are prevailing in diverse conditions and environments such as in microflora of animals [29] and humans [30][31] in soil [32][33] as well as in activated sludge [34]. Numerous examples show that ARGs in human pathogens originated from soil and wastewater bacteria. One of the most well-known examples is blaCTX-M genes, which are the significant root of extended-spectrum b-lactamases (ESBLs) diaspora in *Enterobacteriaceae* globally and the main starting point of clinical treatment complications [35]. These genes' marks were identified from chromosomal DNA of different consensual *Kluyvera* species found in soil and sewage. This can be the origin from where they are disseminated to diverse bacterial species [36]. Likewise, plasmid-encoded qnrA genes, presumed to be originated from fresh marine water species i.e., *Shewanella* algae, which confers Quinolone resistance, with its various *Vibrionaceae* species might also be considered as reservoirs [37]. This spread in different *Enterobacteriaceae* species globally in some areas with a high prevalent rate [38]. Even more, beta-lactamase genes, i.e., OXA-48-type carbapenem-hydrolyzing, progressively reported in various *Enterobacteriaceae* species, were also found to be originated from environmental *Shewanella* species [39]. It is thus believed that many clinically relevant resistance genes are found to be originated from non-pathogenic bacteria underlining the colossal potential of horizontal gene transfer (HGT) for these pathogens in overcoming human use of antibiotics.

4. Emerging Resistance–Development of Resistant Strains

Resistance genes exist in association with genes specifying resistance to other antimicrobials on similar plasmids that lead to multiple drug resistance [40]. The occurrence of MDR plasmids assures the plasmid's presence if any one of the resistances offers survival benefit to the host bacterium. This principle similarly implies every determining factor of resistance to biocides like quaternary ammonium compounds because plasmids bearing

efflux genes exist that offer resistance to antibiotics in *S. aureus* [41]. Some studies show a decline in resistance frequencies when an antibiotic is removed [42]. A noteworthy coast-to-coast setback of macrolide resistance in *Streptococcus pyogenes* occasioned from a Finnish countrywide operation to reduce macrolide practice. In two years, the resistance dropped from about 20% to less than 10%. If a bacterium is resistant to a particular antimicrobial agent, then all the daughter cells would also be resistant (unless additional mutations occurred in the meantime). Persistence, however, describes bacterial cells that are not susceptible to the drug but do not possess resistance genes. The persistence is because some cells in a bacterial population may be in the stationary growth phase (dormant). Most antimicrobial agents do not affect cells that are not actively growing and dividing. These persister cells occur at around 1% in a culture in the stationary phase [43][44]. Figure 2 shows the difference between persistent and resistant bacterial cells. As depicted in Figure 2, persister cells tolerate the antibiotics by changing to a dormant state. These cells do not divide, and they develop tolerance to a high level of antibiotics. Unlike, resistant cells which develop resistance through accumulating mutations, tolerant persister cells are not antibiotic-resistant mutants. Antibiotic tolerance in persister cells is developed through going to a reversible physiological state in a small subpopulation of bacterial cells [45].




Figure 2. Illustration of the comparison of Resistance and Persistence in the bacterial population.

5. ESKAPE, Healthcare Concomitant Bugs–Bad Bugs with No Drugs

ESKAPE is an acronym for the group of pathogens, including Gram-positive and Gram-negative species, comprising *Enterococcus faecium*, *Staphylococcus aureus*, *K. pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, and *Enterobacter species* (Table 1). The Infectious Disease Society of America has started referring to this group of hospital-originated pathogens as ESKAPE [46][47]. These bacteria are usually the reasons behind most life-threatening nosocomial infections amongst immunocompromised and critically ill individuals [7]. Klevens [48] revealed that around 1.7 million people are affected by hospital-acquired infections (HAIs) in the US hospitals, which are responsible for nearly 99,000 deaths each year. A survey of HAI in the United States (US) in 2011 reported a total of about 722,000 reported cases, with 75,000 deaths associated with nosocomial infections [11]. It has also been shown that hospitals using antibiotics are where drug-resistant strains first appeared [46]. For instance, *S. aureus*, which is known to be resistant to penicillin, threatened London’s civilian hospitals soon after the penicillin drug was introduced in the 1940s [7].

Table 1. Narrative of pathogenic bacterial strains (ESKAPE) that instigated nosocomial infection [49].

Bacterial Strain	Gram Staining Type	Resistance Type	Antibiotics	Treatment Option	Resistance Level
<i>Acinetobacter</i>	Negative	Multidrug	Ceftazidime, aminoglycoside, fluoroquinolones, carbapenems	Carbapenems, b-Lactamase inhibitors, Tigecycline, Aminoglycosides, Polymyxin therapy, Synergy, and combination therapy	High level
<i>E. coli</i>	Negative	Multidrug	Cephalosporins (ESBL-producers), fluoroquinolones, aminoglycosides	GyrB/ParE programme, EV-035	High level
<i>K. pneumoniae</i>	Negative	Multidrug	Cephalosporins (ESBL-producers), fluoroquinolones, aminoglycosides, carbapenems	POL7080 and ACHN-975 compounds	High level

Bacterial Strain	Gram Staining Type	Resistance Type	Antibiotics	Treatment Option	Resistance Level
<i>P. aeruginosa</i>	Negative	Multidrug	Piperacillin/tazobactam, ceftazidime, ciprofloxacin, aminoglycosides, carbapenems	POL7080 and ACHN-975 compounds	High level
<i>Enterococcus spp.</i>	Positive	Multidrug	Ampicillin, aminoglycosides, glycopeptides	RX-04 lead series, 50S ribosomal subunit; inhibit translation by stabilizing a distorted mode of P-tRNA binding	High level
<i>S. aureus</i>	Positive,	Multidrug	β -lactam antibiotics (except new anti- methicillin-resistant <i>S. aureus</i> cephalosporins), macrolides, fluoroquinolones, aminoglycosides	RX-04 lead series, 50S ribosomal subunit; inhibit translation by stabilizing a distorted mode of P-tRNA binding	High level

ts. These
iotics [50].

The resistance that microorganisms obtain via biofilm formation can be approximately 1000 folds higher than the resistance obtained at the cellular level [50][51]. The development of resistance at a cellular level is endogenous gene mutations and horizontal gene transfer of resistance determinants through plasmids to other microbes (Figure 3). Apart from resistance, tolerance is also one way to evade antibiotics developed in persister cells, described previously [52]. Both types of resistance may be simultaneous, hence increasing the microbial community's antimicrobial resistance [50] (Table 2).




Figure 3. Illustration of the general mechanism of antimicrobial resistance in bacteria.

Table 2. Types of antimicrobial resistance at the cellular level.

Resistance	Proposed Mechanism	Examples	Ref.
Inactivation of Drug	Use of hydrolysis or modification	b-lactamase for b-lactam resistance, acetyltransferases for aminoglycoside resistance	[53] [54]
Alteration of Target	Reduction of binding affinity to the drug by bypassing the drug target	DNA gyrase mutation for fluoroquinolone resistance	[55]
Drug influx Reduction	By decreasing permeability	Gram-negative outer membrane	[56]

Resistance	Proposed Mechanism	Examples	Ref.
Extrusion of Drug	Efflux pumps	Accessory membrane fusion proteins	[57]
Horizontal gene transfer	By resistance determinants from other microorganisms		[58]

7.1. CRISPR-Cas9

There are several applications of the cutting-edge technology known as Clustered Regularly Interspaced Short Palindromic Repeats and their associated Cas proteins (CRISPR/Cas system). As the CRISPR induces double-strand breaks, one could be the knocking out of a particular bacterial gene. This characteristic of CRISPR/Cas has led to its use to target specific genes for resistance located in plasmids. One of the advantages of using the CRISPR/Cas system is that it has the capability of multiplexing against different targets, which then enables it to target different resistance genes simultaneously. The question arises whether this approach can be effective in the removal of the resistant genes from MDR bacteria that are present in intestinal microbiota or not? The main limitation is to have a collection of appropriate temperate phages designed against multiple resistance genes, and that resistance genes carried by the bacteria should be known. This is feasible in the current situation. It has been observed that phages are well tolerated when they are orally administered [9]. The orally administered phage therapy for bacteria targeting present in the intestinal tract has been a success. However, to avoid bacteriophages' deactivation by acid, the stomach must be passed before using the CRISPR/Cas approaches. However, there is a need to conduct further studies to confirm whether the phages will still be active then they reach the intestinal tract, and if not, how can we make sure of it? There is also a need to know the optimal dose that should be used.

Another advantage of this approach is that without compromising the patients' normal microbiota, susceptibility to antibiotics is restored. Further development of the two approaches discussed above would be revolutionary in the fight against antimicrobial resistance. These techniques could be used for patients with MDR bacteria in various settings to prevent the spread of MDR bacterial strain [59]. On the other hand, the animals have also been shown to play an essential role in reservoirs of MDR bacteria. Therefore, these techniques can also be used for them.

7.2. Nanotechnology and Nanoparticles to Combat Multidrug Resistance

Several hypotheses have been put forwarded for the mechanism of nanoparticles of metals and metal oxides. The hypothesis includes protein dysfunction, physically disrupting the cell structure, generation of reactive oxygen species and depletion of antioxidants, impairing of membrane and interfering with the nutrient assimilation and use of dephosphorylation of the peptide substrates on tyrosine residues which help to alter the signal transduction resulting in its inhibition and suppressing the bacterial growth [60]. The nanoparticles derived from zinc oxide and silver can penetrate the bacterial cell wall and result in changes of its cell membrane, which causes structural damage; hence, the integrity of the membrane is lost, leading to cell death [61][62].

Silver nanoparticles are also known to mount on the cell wall and form pits in it, while gold nanoparticles apply their antibacterial activities by disintegrating the bacterial cell membrane [63]. Apart from these mechanisms, there is another mechanism in which free radicals are produced to generate oxidative stress. These generated reactive oxygen species can destroy the bacteria by destroying its DNA, membrane, and mitochondria, hence ultimately killing the bacterial cell [64]. However, there is a chance that the bacterial cells, to fight these reactive oxygen species, may produce more detoxification enzymes [65]. The metallic nanoparticles can interact with phosphorus and sulfur, present in biomaterials in bacterial cells like DNA bases. Hence, these can help destroy DNA resulting in killing the cell [66], (Table 3). Some of the possible action mechanisms of nanoparticle-induced death of bacteria are shown in Figure 4.




Figure 4. Suggested action mechanisms of metallic nanoparticles against gram-negative bacteria. Adopted from [67].

Table 3. Mechanism of bactericidal activity of Nanoparticles and synergic effect of antibiotic-conjugated metal oxide nanoparticles against ESKAPE Pathogen.

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
AgNPs	Damage the bacterial cell membrane and	Doxycycline	<i>K. pneumoniae</i>	Observed	[68]

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
	disrupt the activity of membranous enzymes. Cell wall distraction by cell DNA was condensed to a tension state and could have lost its replicating abilities	Gentamicin and Neomycin	<i>S. aureus</i>	AgNPs + Gentamicin showed resistance in 50% strains while AgNPs + Neomycin showed synergy 45% of the strains.	[69]
			<i>E. coli, S. aureus</i>	Observed increase in activity was such that Erythromycin showed 18.9.6%, Kanamycin = 27.9.3%, Chloramphenicol = 18.1.3%, and Ampicillin = 74.8.9%	[69]
		β-Lactam, cefotaxime	<i>E. coli, S. aureus</i>	Synergistic increase in activity was such that 17.2%, 13.5% for <i>E. coli</i> and <i>S. aureus</i> , respectively	[70]
		Ampicillin, chloramphenicol, and kanamycin	<i>S. aureus, E. coli,</i>	Synergistic effects observed	[71]

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
		and <i>P. aeruginosa</i>			
		Beta-lactam: cephem	<i>S. aureus</i>	Cephalothin and cefazolin showed a 30% increase in activity when used in combination with 20 µg/ mL AgNPs against <i>Micrococcus luteus</i> , and <i>Bacillus subtilis</i>	[72]
AuNPs	Disturb membrane potential by inhibiting ATPase activities; inhibit the subunit of the ribosome from binding tRNA. Cellular death induced by gold nanoparticles do not include reactive oxygen species-based mechanisms	Ampicillin, streptomycin, and kanamycin	<i>E. coli</i> and <i>S. aureus</i>	15%, 12%, and 34% increase in inhibition zone for <i>E. coli</i> with A/S/K+Au, respectively; 20%, 109%, and 18% increase in inhibition zone for <i>M. luteus</i> A/S/K+AuNPs, respectively; 12% and 34% increase in inhibition zone for <i>S. aureus</i> with A/ K+AuNPs, respectively	[73]

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
		Beta lactams: cefaclor	<i>S. aureus</i> and <i>E. coli</i>	MICs of cefaclor reduced gold nanoparticles were 10 mg/mL and 100 mg/mL for <i>S. aureus</i> and <i>E. coli</i> , respectively	[74]
ZnONPs	Interactions between reactive oxygen species and membrane proteins result in cell damage. ZnO-NPs disrupt bacterial cell membrane integrity, reduce cell surface hydrophobicity, and down-regulate the transcription of oxidative stress-resistance genes in bacteria	Ceftriaxone	<i>E. coli</i>	Synergistic antibacterial effects against <i>E. coli</i> have been observed by ZnO nanorods with ceftriaxone	[75]
		Ciprofloxacin	<i>S. aureus</i> and <i>E. coli</i>	Increase in inhibition zones in <i>S. aureus</i> = 27% and 22% in <i>E. coli</i> when ciprofloxacin and ZnONPs were applied in synergism	[76]
		Beta lactams, aminoglycosides, and azolides	<i>S. aureus</i>	The highest increase was observed for penicillin G and amikacin, i.e., 10 mm increase in the zone of inhibition,	[77]

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
				whereas for clarithromycin, a 2 mm increase had been observed	
TiO ₂ NPs	Electrostatic interaction between TiO ₂ NPs and the bacterial cell surface results in suppression of cell division, degradation of the cell wall and cytoplasmic membrane due to the production of reactive oxygen species such as hydroxyl radicals and hydrogen peroxide	Penicillin G, amikacin, cephalexin, cefotaxime	MRSA	10 mm increase in zone size. TiO ₂ nanoparticles significantly improved antibiotic efficacy against <i>S. aureus</i> when combined with beta-lactams, cephalosporins, and aminoglycosides	[78]
Fe ₃ O ₄ NPs	Generation of reactive oxygen species from the disruption of the electronic transport chains owing to the resilient affinity of the iron-based nanoparticles for the cell membrane.	Streptomycin	<i>S. aureus</i> , <i>E. coli</i> , and <i>P. aeruginosa</i>	Zones of inhibition at concentrations (10, 20, 40, and 80): <i>S. aureus</i> (15 mm, 14 mm, 17 mm, 20 mm), <i>E. coli</i> (12 mm, 14 mm, 15 mm, 17 mm), <i>P. aeruginosa</i> (13	[79][80][81]

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
	Reactive oxygen species generated by Fe3O4 nanoparticles kill bacteria without harming non-bacterial cells			mm, 14 mm, 15 mm, 18 mm)	
		Kanamycin and rifampicin	<i>E. coli</i> and <i>S. aureus</i>	Kanamycin formed an inhibition zone against both, whereas rifampicin formed an inhibitory zone against <i>S. aureus</i> only	[81]
		Amoxicillin	<i>E. coli</i> and <i>S. aureus</i>	A total of 9.9% and 8.9% increase in inhibitory effect observed in the presence of Cu NPs for <i>E. coli</i> and <i>S. aureus</i> , respectively	[80]
CuNPs	Generation of reactive oxygen species, lipid peroxidation, protein oxidation, and DNA degradation. Cu2+ ions released from nanoparticles penetrate bacterial cells and are	Amikacin, ciprofloxacin, gentamicin, norfloxacin	<i>E. coli</i> , <i>P. aeruginosa</i> , <i>Klebsiella spp.</i> <i>S. aureus</i>	At 60 mg/mL, 18 mm for <i>E. coli</i> , 16 mm for <i>Klebsiella</i>	[82]

2. Price, N.; Klein, J.L. Infectious Diseases and Emergencies; Oxford University Press (OUP): Oxford, UK, 2016.

Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.
	subsequently oxidized intracellularly				
BiNPs	Production of reactive oxygen species	Ciprofloxacin, norfloxacin, tetracycline, and metronidazole	<i>K. pneumoniae</i>	A synergistic effect was observed between all antibiotics and BiNPs.	[83]
		Cefotaxime, ampicillin, ceftriaxone, cefepime	<i>E. coli</i> , <i>K. pneumoniae</i> , and <i>P.aeruginosa</i>	Significant decrease in MIC decrease with cefotaxime and ZnO NPs against <i>K. pneumoniae</i> (85.7%), <i>P. aeruginosa</i> (70%), and <i>E. coli</i> (50%) has been observed. Meanwhile, a decrease in MIC due to ZnO NP with other antibiotics has been observed.	[84]
		Norfloxacin, Ofloxacin, and Cephalexin	<i>P. aeruginosa</i> , <i>E. coli</i>	Significant increase in inhibition zone of antibiotics with	[67]

1. ... Woodruff, M., Parson, S., Livermore, D.M. Multiresistant Gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 2011, 35, 736–755.

1	Nanoparticles (NP)	Mode of Action/Mechanism of Nanoparticles Against ESKAPE Pathogens	Antibiotic Used	Microorganism	Synergic Effects (Antibiotics-Nanoparticles)	Ref.	IS.
1							other.
2					ZnONPshave been observed against all isolates.		in 003, 47,
	2831–2837.						

21. Piddock, L.J. Mechanisms of fluoroquinolone resistance: An update 1994–1998. *Drugs* 1999, 58, 11–18.

22. Hiramatsu, K. Vancomycin resistance in staphylococci. *Drug Resist. Updat.* 1998, 1, 135–150.

23. Weigel, L.M.; Clewell, D.B.; Gill, S.R.; Clark, N.C.; McDougal, L.K.; Flannagan, S.E.; Kolonay, J.F.; Shetty, J.; Killgore, G.E.; Tenover, F.C. Genetic analysis of a high-level vancomycin-resistant isolate of *Staphylococcus aureus*. *Science* 2003, 302, 1569–1571.

24. Tenover, F.C.; Weigel, L.M.; Appelbaum, P.C.; McDougal, L.K.; Chaitram, J.; McAllister, S.; Clark, N.; Killgore, G.; O’Hara, C.M.; Jevitt, L.; et al. Vancomycin-resistant *Staphylococcus aureus* isolate from a patient in Pennsylvania. *Antimicrob. Agents Chemother.* 2004, 48, 275–280.

25. Lipsitch, M.; Samore, M.H. Antimicrobial use and antimicrobial resistance: A population perspective. *Emerg. Infect. Dis.* 2002, 8, 347–354.

26. Schmieder, R.; Edwards, R. Insights into antibiotic resistance through metagenomic approaches. *Futur. Microbiol.* 2012, 7, 73–89.

27. Karkman, A.; Do, T.T.; Walsh, F.; Virta, M.P. Antibiotic-resistance genes in waste water. *Trends Microbiol.* 2018, 26, 220–228.

28. Allen, H.K.; Donato, J.; Wang, H.H.; Cloud-Hansen, K.A.; Davies, J.; Handelsman, J. Call of the wild: Antibiotic resistance genes in natural environments. *Nat. Rev. Microbiol.* 2010, 8, 251–259.

29. Wichmann, F.; Udikovic-Kolic, N.; Andrew, S.; Handelsman, J. Diverse antibiotic resistance genes in dairy cow manure. *mBio* 2014, 5, e01017-13.

30. Clemente, J.C.; Pehrsson, E.C.; Blaser, M.J.; Sandhu, K.; Gao, Z.; Wang, B.; Magris, M.; Hidalgo, G.; Contreras, M.; Noya-Alarcón, Ó.; et al. The microbiome of uncontacted Amerindians. *Sci. Adv.* 2015, 1, e1500183.

31. Moore, A.M.; Ahmadi, S.; Patel, S.; Gibson, M.K.; Wang, B.; Ndao, I.M.; Deych, E.; Shannon, W.D.; Tarr, P.I.; Warner, B.B.; et al. Gut resistome development in healthy twin pairs in the first year of life. *Microbiome* 2015, 3, 1–10.

32. Donato, J.J.; Moe, L.A.; Converse, B.J.; Smart, K.D.; Berklein, F.C.; McManus, P.S.; Handelsman, J. Metagenomic analysis of apple orchard soil reveals antibiotic resistance genes encoding predicted bifunctional proteins. *Appl. Environ. Microbiol.* 2010, 76, 4396–4401.
33. Perron, G.G.; Whyte, L.; Turnbaugh, P.J.; Goordial, J.; Hanage, W.P.; Dantas, G.; Desai, M.M. Functional characterization of bacteria isolated from ancient arctic soil exposes diverse resistance mechanisms to modern antibiotics. *PLoS ONE* 2015, 10, e0069533.
34. Parsley, L.C.; Consuegra, E.J.; Kakirde, K.S.; Land, A.M.; Harper, W.F.; Liles, M.R. Identification of diverse antimicrobial resistance determinants carried on bacterial, plasmid, or viral metagenomes from an activated sludge microbial assemblage. *Appl. Environ. Microbiol.* 2010, 76, 3753–3757.
35. Hawkey, P.M.; Jones, A.M. The changing epidemiology of resistance. *J. Antimicrob. Chemother.* 2009, 64 (Suppl. S1), i3–i10.
36. Cantón, R.; Coque, T.M. The CTX-M β -lactamase pandemic. *Curr. Opin. Microbiol.* 2006, 9, 466–475.
37. Poirel, L.; Liard, A.; Rodriguez-Martinez, J.-M.; Nordmann, P. Vibrionaceae as a possible source of Qnr-like quinolone resistance determinants. *J. Antimicrob. Chemother.* 2005, 56, 1118–1121.
38. Minh, N.N.Q.; Thuong, T.C.; Khuong, H.D.; Nga, T.V.T.; Thompson, C.; Campbell, J.I.; De Jong, M.; Farrar, J.J.; Schultsz, C.; Van Doorn, H.R.; et al. The co-selection of fluoroquinolone resistance genes in the gut flora of vietnamese children. *PLoS ONE* 2012, 7, e42919.
39. Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like carbapenemases: The phantom menace. *J. Antimicrob. Chemother.* 2012, 67, 1597–1606.
40. Summers, A.O. Generally overlooked fundamentals of bacterial genetics and ecology. *Clin. Infect. Dis.* 2002, 34 (Suppl. S3), S85–S92.
41. Sidhu, M.S.; Heir, E.; Leegaard, T.; Wiger, K.; Holck, A. Frequency of disinfectant resistance genes and genetic linkage with β -lactamase transposon Tn552 among clinical staphylococci. *Antimicrob. Agents Chemother.* 2002, 46, 2797–2803.
42. Barbosa, T.M.; Levy, S.B. The impact of antibiotic use on resistance development and persistence. *Drug Resist. Updat.* 2000, 3, 303–311.
43. Weinstein, R.A. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. *Emerg. Infect. Dis.* 2001, 7, 188–192.
44. Gagliotti, C.; Balode, A.; Baquero, F.; Degener, J.; Grundmann, H.; Gür, D.; Jarlier, V.; Kahlmeter, G.; Monen, J.; Monnet, D.; et al. *Escherichia coli* and *Staphylococcus aureus*: Bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. *Eurosurveillance* 2011, 16, 19819.

45. Lewis, K. Persister cells, dormancy and infectious disease. *Nat. Rev. Microbiol.* 2007, 5, 48–56.
46. Rice, L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. *J. Infect Dis.* 2008, 197, 1079–1081.
47. Bush, K.; Jacoby, G.A. Updated Functional Classification of β -Lactamases. *Antimicrob. Agents Chemother.* 2010, 54, 969–976.
48. Klevens, R.M.; Edwards, J.R.; Richards, C.L., Jr.; Horan, T.C.; Gaynes, R.P.; Pollock, D.A.; Cardo, D.M. Estimating health care-associated infections and deaths in US hospitals, 2002. *Pub. Health Rep.* 2007, 122, 160–166.
49. Theuretzbacher, U. Global antibacterial resistance: The never-ending story. *J. Glob. Antimicrob. Resist.* 2013, 1, 63–69.
50. Penesyan, A.; Gillings, M.; Paulsen, I. Antibiotic discovery: Combatting bacterial resistance in cells and in biofilm communities. *Molecules* 2015, 20, 5286–5298.
51. Hegstad, K.; Langsrud, S.; Lunestad, B.T.; Scheie, A.A.; Sunde, M.; Yazdankhah, S.P. Does the wide use of quaternary ammonium compounds enhance the selection and spread of antimicrobial resistance and thus threaten our health? *Microb. Drug Resist.* 2010, 16, 91–104.
52. Maisonneuve, E.; Gerdes, K. Molecular mechanisms underlying bacterial persisters. *Cell* 2014, 157, 539–548.
53. Shaw, K.; Rather, P.; Hare, R.; Miller, G. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microbiol. Mol. Biol. Rev.* 1993, 57, 138–163.
54. Bush, K.; Fisher, J.F. Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β -Lactamases from Gram-Negative Bacteria. *Annu. Rev. Microbiol.* 2011, 65, 455–478.
55. Hooper, D.C.; Jacoby, G.A. Mechanisms of drug resistance: Quinolone resistance. *Ann. N. Y. Acad. Sci.* 2015, 1354, 12–31.
56. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol. Mol. Biol. Rev.* 2003, 67, 593–656.
57. Li, X.-Z.; Plésiat, P.; Nikaido, H. The Challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin. Microbiol. Rev.* 2015, 28, 337–418.
58. D’Costa, V.M.; McGrann, K.M.; Hughes, D.W.; Wright, G.D. Sampling the Antibiotic Resistome. *Science* 2006, 311, 374–377.
59. Arcilla, M.S.; van Hattem, J.M.; Haverkate, M.R.; Bootsma, M.C.; van Genderen, P.J.; Goorhuis, A.; Grobusch, M.P.; Lashof, A.M.O.; Molhoek, N.; Schultsz, C.; et al. Import and spread of

- extended-spectrum β -lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): A prospective, multicentre cohort study. *Lancet Infect. Dis.* 2017, 17, 78–85.
60. Lemire, J.A.; Harrison, J.J.; Turner, R.J. Antimicrobial activity of metals: Mechanisms, molecular targets and applications. *Nat. Rev. Microbiol.* 2013, 11, 371–384.
 61. Zhang, Y.-M.; Rock, C.O. Membrane lipid homeostasis in bacteria. *Nat. Rev. Genet.* 2008, 6, 222–233.
 62. Prabhu, S.; Poulouse, E.K. Silver nanoparticles: Mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. *Int. Nano Lett.* 2012, 2, 32.
 63. Cui, Y.; Zhao, Y.; Tian, Y.; Zhang, W.; Lü, X.; Jiang, X. The molecular mechanism of action of bactericidal gold nanoparticles on *Escherichia coli*. *Biomaterials* 2012, 33, 2327–2333.
 64. Soenen, S.J.; Rivera-Gil, P.; Montenegro, J.-M.; Parak, W.J.; De Smedt, S.C.; Braeckmans, K. Cellular toxicity of inorganic nanoparticles: Common aspects and guidelines for improved nanotoxicity evaluation. *Nano Today* 2011, 6, 446–465.
 65. Jin, Y.H.; Dunlap, P.E.; McBride, S.J.; Al-Refai, H.; Bushel, P.R.; Freedman, J.H. Global transcriptome and deletome profiles of yeast exposed to transition metals. *PLoS Genet.* 2008, 4, e1000053.
 66. Feng, Q.L.; Wu, J.; Chen, G.; Cui, F.; Kim, T.; Kim, J. A mechanistic study of the antibacterial effect of silver ions on *Escherichia coli* and *Staphylococcus aureus*. *J. Biomed. Mat. Res.* 2000, 52, 662–668.
 67. Muzammil, S.; Hayat, S.; Fakhar-E-Alam, M.; Aslam, B.; Siddique, M.; Nisar, M.; Saqalein, M.; Atif, M.; Sarwar, A.; Khurshid, A. Nanoantibiotics: Future nanotechnologies to combat antibiotic resistance. *Front Biosci.* 2018, 10, 352–374.
 68. Jamaran, S.; Zarif, B.R. Synergistic effect of silver nanoparticles with neomycin or gentamicin antibiotics on mastitis-causing *Staphylococcus aureus*. *Open J. Ecol.* 2016, 6, 452–459.
 69. Fayaz, A.M.; Balaji, K.; Girilal, M.; Yadav, R.; Kalaichelvan, P.T.; Venketesan, R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: A study against gram-positive and gram-negative bacteria. *Nanomedicine Nanotechnol. Biol. Med.* 2010, 6, 103–109.
 70. Hassan, M.; Ismail, M.; Moharram, A.; Shoreit, A. Synergistic Effect of Biogenic Silver-nanoparticles with β lactam Cefotaxime against Resistant *Staphylococcus arlettae* AUMC b-163 Isolated from T3A Pharmaceutical Cleanroom, Assiut, Egypt. *Am. J. Microbiol. Res.* 2016, 4, 132–137.
 71. Hwang, I.-s.; Hwang, J.H.; Choi, H.; Kim, K.-J.; Lee, D.G. Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. *J. Med. Microbiol.* 2012, 61, 1719–1726.

72. Hari, N.; Thomas, T.K.; Nair, A.J. Comparative Study on the Synergistic Action of Differentially Synthesized Silver Nanoparticles with β -Cephem Antibiotics and Chloramphenicol. *J. Nanosci.* 2014, 2014, 1–8.
73. Saha, B.; Bhattacharya, J.; Mukherjee, A.; Ghosh, A.; Santra, C.; Dasgupta, A.K.; Karmakar, P. In vitro structural and functional evaluation of gold nanoparticles conjugated antibiotics. *Nanoscale Res. Lett.* 2007, 2, 614–622.
74. Rai, A.; Prabhune, A.; Perry, C.C. Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. *J. Mater. Chem.* 2010, 20, 6789–6798.
75. Luo, Z.; Wu, Q.; Xue, J.; Ding, Y. Selectively enhanced antibacterial effects and ultraviolet activation of antibiotics with ZnO nanorods against *Escherichia coli*. *J. Biomed. Nanotechnol.* 2013, 9, 69–76.
76. Banoei, M.; Seif, S.; Nazari, Z.E.; Jafari-Fesharaki, P.; Shahverdi, H.R.; Moballegh, A.; Moghaddam, K.M.; Shahverdi, A.R. ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against *Staphylococcus aureus* and *Escherichia coli*. *J. Biomed. Mat. Res. Part B Appl. Biomater.* 2010, 93, 557–561.
77. Thati, V.; Roy, A.S.; Ambika Prasad, M.; Shivannavar, C.; Gaddad, S. Nanostructured zinc oxide enhances the activity of antibiotics against *Staphylococcus aureus*. *J. Biosci. Tech.* 2010, 1, 64–69.
78. Roy, A.S.; Parveen, A.; Koppalkar, A.R.; Prasad, M.A. Effect of nano-titanium dioxide with different antibiotics against methicillin-resistant *Staphylococcus aureus*. *J. Biomater. Nanobiotechnol.* 2010, 1, 37–41.
79. Kooti, M.; Gharineh, S.; Mehrkhah, M.; Shaker, A.; Motamedi, H. Preparation and antibacterial activity of CoFe₂O₄/SiO₂/Ag composite impregnated with streptomycin. *Chem. Eng. J.* 2015, 259, 34–42.
80. Khashan, K.S.; Sulaiman, G.M.; Abdulameer, F.A. Synthesis and antibacterial activity of CuO nanoparticles suspension induced by laser ablation in liquid. *Arab. J. Sci. Eng.* 2016, 41, 301–310.
81. Patra, J.K.; Ali, M.S.; Oh, I.-G.; Baek, K.-H. Proteasome inhibitory, antioxidant, and synergistic antibacterial and anticandidal activity of green biosynthesized magnetic Fe₃O₄ nanoparticles using the aqueous extract of corn (*Zea mays* L.) ear leaves. *Artif. Cells Nanomed. Biotechnol.* 2017, 45, 349–356.
82. Tanna, J.A.; Chaudhary, R.G.; Gandhare, N.V.; Rai, A.R.; Yerpude, S.; Juneja, H.D. Copper nanoparticles catalysed an efficient one-pot multicomponents synthesis of chromenes derivatives and its antibacterial activity. *J. Exp. Nanosci.* 2016, 11, 884–900.

83. Tarjoman, Z.; Ganji, S.M.; Mehrabian, S. Synergistic effects of the bismuth nanoparticles along with antibiotics on PKS positive *Klebsiella pneumoniae* isolates from colorectal cancer patients; comparison with quinolone antibiotics. *M. Res. J. Med. Med. Sci.* 2015, 3, 387–393.
84. Bhande, R.M.; Khobragade, C.N.; Mane, R.S.; Bhande, S. Enhanced synergism of antibiotics with zinc oxide nanoparticles against extended spectrum β -lactamase producers implicated in urinary tract infections. *J. Nanopart. Res.* 2013, 15, 1413.
-

Retrieved from <https://encyclopedia.pub/entry/history/show/24411>